Assessing the impact of multi-compartment compliance aids on clinical outcomes in the elderly: a pilot study

Mosca, C; Castel‐Branco, Margarida; Ribeiro-Rama, A.C.; Caramona, Margarida; Fernández-Llimós, Fernando; Figueiredo, Isabel V.

doi:10.1007/s11096-013-9852-2

Cited by 12 publications

(9 citation statements)

References 32 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite their use, there is scant evidence that MCAs improve medicines adherence or lead to greater involvement in decision making [17][18][19]. Nunney et al reported a qualitative study of older people living independently in the community and an unrelated sample of health professionals involved in the supply of MCAs [20].…”

Section: Introductionmentioning

confidence: 99%

A Case Study Investigation into the Use of Multi-compartment Compliance Aids in Older People Resident in Very Sheltered Housing

MacLure

MacLeod

Forbes-McKay

et al. 2016

Patient

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

A Case Study Investigation into the Use of Multi-compartment Compliance Aids in Older People Resident in Very Sheltered Housing

MacLure

MacLeod

Forbes-McKay

et al. 2016

Patient

View full text Add to dashboard Cite

“…38 Multi-compartment compliance aids (MCAs) (e.g., refrigerator magnets, stickers on mirrors, pill container for weekly/monthly use, and electronic reminder devices (timed alarms, watches, smart phones, and medication containers with chips) were used to assess self-reported adherence and clinical biomarkers of elderly patients followed in a community pharmacy. All received regular pharmacy counselling.…”

Section: Resultsmentioning

confidence: 99%

Validity of Behavioral Measures as Proxies for HIV-Related Outcomes

Zimmerman¹,

Morisky²,

Harrison³

et al. 2014

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Over the last 30 years, expectations for the quality, validity, and objectivity of the outcome measures used to assess the impact of behavior change interventions related to HIV have steadily increased. At this point (mid-2014 at this writing), biological evidence or biomarkers of the incidence of HIV and other sexually transmitted infections [STI] in a target population is clearly preferable to self-reports of behavior. This kind of evidence is, however, much more expensive to collect than participants’ reports of behavior change (e.g., increased condom use, reduced substance use or abstinence from substance use, and high levels of medication adherence). In addition, while potentially less subject to reporting bias, biomarkers and biological outcomes have their own flaws. In this paper we review the literature on the validity of self-reports of outcomes most relevant to HIV behavior change interventions, sexual behavior (ever having had sex and condom use), substance use, and medication adherence. We note the extent to which they may be adequate outcome measures without biological data, and the conditions under which they may be most likely to be sufficient. We also argue, like many others, that where possible, both self-report and biological measures should be collected.

show abstract

“…This should include not only attributes with a strong impact on the biopharmaceutical performances of the drug product but also those with an influence on the adherence of the patients, such as the handling and dosing. In this light, the use of multi-compartment medication devices has been demonstrated to be effective in supporting older patients in their daily regimens and in improving clinical outcomes [39,40]. Indeed, such tools permit the patient/caregiver to organize in advance the medicines to take in a specific day period (e.g., morning, evening) or day of the week, reducing the risk of medication errors and simplifying the actions that patients have to do for medicine administration.…”

Section: Elderlymentioning

confidence: 99%

Patient Centric Pharmaceutical Drug Product Design—The Impact on Medication Adherence

et al. 2020

View full text Add to dashboard Cite

Medication adherence is a growing concern for public health and poor adherence to therapy has been associated with poor health outcomes and higher costs for patients. Interventions for improving adherence need to consider the characteristics of the individual therapeutic regimens according to the needs of the patients. In particular, geriatric and paediatric populations as well as dermatological patients have special needs/preferences that should be considered when designing drug products. Patient Centric Drug Product Pharmaceutical Design (PCDPD) offers the opportunity to meet the needs and preferences of patients. Packaging, orodispersible formulations, fixed dose combinations products, multiparticulate formulations, topical formulations and 3D printing are of particular relevance in a PCDPD process. These will be addressed in this review as well as their impact on medication adherence.

show abstract

Assessing the impact of multi-compartment compliance aids on clinical outcomes in the elderly: a pilot study

Cited by 12 publications

References 32 publications

A Case Study Investigation into the Use of Multi-compartment Compliance Aids in Older People Resident in Very Sheltered Housing

A Case Study Investigation into the Use of Multi-compartment Compliance Aids in Older People Resident in Very Sheltered Housing

Validity of Behavioral Measures as Proxies for HIV-Related Outcomes

Patient Centric Pharmaceutical Drug Product Design—The Impact on Medication Adherence

Contact Info

Product

Resources

About